The integration of PI3K/AKT pathway inhibitors into advanced breast cancer treatment has expanded therapeutic options, yet successful implementation requires careful attention to adverse event management.1 A proactive, interdisciplinary approach proves essential for maintaining both treatment efficacy and patient quality of life.2
Common adverse events associated with these targeted therapies include diarrhea, severe skin reactions, and hyperglycemia.1,3 Understanding the predictable nature of these toxicities allows clinicians to implement preventive strategies and early interventions that support treatment continuation.
Baseline assessment plays a crucial role in risk stratification. Measuring hemoglobin A1c before treatment initiation could identify patients who may require enhanced glucose monitoring throughout therapy.4 This proactive screening enables individualized monitoring protocols tailored to each patient’s metabolic risk profile.
Management strategies involve both pharmacologic interventions and dose modifications. Antidiarrheals, antihistamines, topical corticosteroids, and glucose-lowering agents can effectively control common toxicities when initiated early.3,4 When adverse events become more challenging, dose modifications, treatment delays, or temporary interruptions offer effective approaches to managing reversible toxicities without permanently discontinuing therapy.
Patient and caregiver education forms the foundation of successful adverse event management. Comprehensive counseling about potential toxicities, warning signs requiring immediate attention, and self-management strategies empowers patients as active participants in their care.2 Frequent monitoring enables early recognition of emerging issues and timely intervention.
The goal extends beyond simply managing toxicities, it encompasses preserving treatment efficacy while maintaining the daily functioning and well-being that patients prioritize. This balanced, team-based approach requires ongoing communication, flexible management strategies, and recognition that optimal adverse event management directly correlates with improved treatment adherence and outcomes.
Take our metastatic breast cancer quiz to see how your knowledge compares to your peers.
